Dyne Therapeutics (DYN) to Release Earnings on Thursday

Dyne Therapeutics (NASDAQ:DYN) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Dyne Therapeutics to post earnings of ($0.74) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $15.45 on Tuesday. The firm has a market cap of $2.21 billion, a P/E ratio of -4.22 and a beta of 1.30. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $25.00. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14. The company has a 50 day moving average of $17.84 and a 200 day moving average of $16.89.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DYN. HC Wainwright boosted their price target on Dyne Therapeutics from $46.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Sanford C. Bernstein set a $23.00 target price on Dyne Therapeutics in a research report on Tuesday, December 9th. Evercore lowered their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Finally, Oppenheimer raised shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $11.00 to $40.00 in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.41.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently modified their holdings of the business. Aster Capital Management DIFC Ltd bought a new position in Dyne Therapeutics in the 4th quarter worth $84,000. Steward Partners Investment Advisory LLC increased its position in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. Prudential Financial Inc. purchased a new position in shares of Dyne Therapeutics during the 2nd quarter valued at about $111,000. Finally, Creative Planning lifted its position in shares of Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after buying an additional 2,797 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.